Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: A multicenter experience

Xinqing Lin, Haiyi Deng, Likun Chen, Di Wu, Xiaobo Chen, Yilin Yang, Tao Chen, Xiaohong Xie, Zhanhong Xie, Ming Liu, Ming Ouyang, Yinyin Qin, Shiyue Li, Nanshan Zhong, Jeffrey P. Gregg, Nobuyuki Horita, Yong Song, Chengzhi Zhou

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Checkpoint inhibitor-related pneumonitis (CIP) is not well classified according to clinical factors. We propose different clinical sub-types of CIP based on clinical factors and investigated the corresponding clinical features, treatments, and outcomes. Methods: We conducted a multicenter retrospective study of patients with lung cancer (including non-small cell lung cancer and small cell lung cancer) who developed CIP. The clinical characteristics, radiologic features, treatments, and outcomes of CIP were analyzed. Results: A total of 55 patients developed CIP and were classified into 3 groups as follows: 21 in the pure type (PT) group, 14 in the induced type (IT) group, and 20 in the mixed type (MT) group. The incidence of severe (grade 3-5) pneumonitis was significantly higher in the IT group than in the PT and MT groups (71.4% vs. 14.3% vs. 50.0%, P=0.002). Antiviral therapy was significantly more frequent in the IT group than in the PT and MT groups. Antibiotic therapy was administered in 23.8%, 71.4%, and 80.0% of patients with the PT, IT, and MT, respectively. The improvement time in the PT group was longer than that in the IT and MT groups (0.9 vs. 0.5 vs. 0.3 months, P=0.028). Patients with the PT had a better tumor response to immune checkpoint inhibitors (ICIs) than those with the other 2 types [overall response rate (ORR), 78% vs. 31% vs. 44%, P=0.027]. Conclusions: The clinical classification of CIP may favor strategies for treatments and predict the tumor response to ICIs.

Original languageEnglish (US)
Pages (from-to)415-429
Number of pages15
JournalTranslational Lung Cancer Research
Volume10
Issue number1
DOIs
StatePublished - Jan 2021

Keywords

  • Checkpoint inhibitor-related pneumonitis (CIP)
  • Clinical types
  • Immune checkpoint inhibitor (ICI)
  • Immune-related adverse events
  • Lung cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: A multicenter experience'. Together they form a unique fingerprint.

Cite this